We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Kazia Therapeutics is a biotechnology business based in Australia. Kazia Therapeutics shares (KZA) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Kazia Therapeutics has a trailing 12-month revenue of around $15.2 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| 52-week range | $0.585 - $1.65 |
|---|---|
| 50-day moving average | $0.8179 |
| 200-day moving average | $1.116 |
| Target price | $1.9 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.116 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.625
| 1 week (2022-06-28) | 1.63% |
|---|---|
| 1 month (2022-06-03) | -22.84% |
| 3 months (2022-04-05) | -42.92% |
| 6 months (2022-01-05) | -48.77% |
| 1 year (2021-07-05) | -54.55% |
|---|---|
| 2 years (2020-07-03) | 22.55% |
| 3 years (2019-07-05) | 56.25% |
| 5 years (2017-07-05) | -86.98% |
| Revenue TTM | $15.2 million |
|---|---|
| Gross profit TTM | $15.2 million |
| Return on assets TTM | -19.59% |
| Return on equity TTM | -52.76% |
| Profit margin | -99.27% |
| Book value | 0.193 |
| Market capitalisation | $82.8 million |
TTM: trailing 12 months
We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.
Kazia Therapeutics 's shares were split on a 1:10 basis on 17 November 2017. So if you had owned 10 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics 's share price.
Over the last 12 months, Kazia Therapeutics 's shares have ranged in value from as little as $0.585 up to $1.65. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Kazia Therapeutics 's is 2.767. This would suggest that Kazia Therapeutics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
